For men facing a prostate biopsy, one of the biggest fears is whether the procedure will harm their sexual function. A new analysis of existing research offers some clarity, but also a note of caution. The review looked at two common biopsy methods—one through the rectum and one through the perineum (the area behind the scrotum). It found that both approaches are associated with a dip in erectile function one month after the procedure. Interestingly, the perineal approach showed a slightly more significant initial decline, though the difference between the two methods wasn't strong enough to be considered definitive. The good news is that this effect appears to be temporary. By three months, the overall difference between the biopsy methods faded, and by six months, erectile function generally returned to its pre-biopsy baseline. This analysis pooled data from 12 different studies, which gives it more weight than a single report. However, it can't prove the biopsy itself caused the decline—it only shows an association. The findings provide solid evidence for doctors to use when counseling patients about what to expect, helping to manage fears about long-term sexual health impacts.
Meta-analysis finds transient erectile dysfunction after prostate biopsy, resolves by 6 monthsDoes prostate biopsy affect sexual function? A temporary dip, then recovery
AI-generated summary of the cited source, checked by automated accuracy review. How we work
This meta-analysis of 12 studies evaluated erectile function in men undergoing prostate biopsy, comparing transperineal (TP) and transrectal (TR) approaches. The primary outcome was erectile function measured by IIEF scores at 1, 3, and 6 months post-procedure. The analysis included men undergoing prostate biopsy, though specific study settings were not reported.
At 1 month post-biopsy, there was a significant overall decline in erectile function (SMD: -0.3785, p = 0.038). The TP approach showed a slightly more significant decline than TR, though this difference was not statistically significant (p = 0.074). At 3 months, no significant differences were observed between methods overall (SMD: -0.1663, p = 0.132), though TP biopsy alone showed a modest yet considerable decline (SMD: -0.1868, p = 0.03). By 6 months, erectile function generally returned to baseline with no significant differences between techniques (p = 0.41).
Safety and tolerability data were not reported in the meta-analysis. Limitations include potential heterogeneity across the 12 included studies and lack of reported absolute numbers for effect sizes. The findings provide evidence-based guidance for patient counseling, suggesting both biopsy techniques are associated with a transient decline in erectile function that typically resolves within 6 months, with no clear long-term advantage for either approach regarding erectile outcomes.